S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)

PDS Biotechnology Stock Price, News & Analysis (NASDAQ:PDSB)

$5.24
-0.04 (-0.76%)
(As of 02:46 PM ET)
Compare
Today's Range
$5.19
$5.36
50-Day Range
$3.95
$6.58
52-Week Range
$3.80
$13.65
Volume
227,140 shs
Average Volume
607,950 shs
Market Capitalization
$163.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

PDS Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
237.2% Upside
$17.67 Price Target
Short Interest
Bearish
16.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

872nd out of 949 stocks

Pharmaceutical Preparations Industry

401st out of 427 stocks


PDSB stock logo

About PDS Biotechnology Stock (NASDAQ:PDSB)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Stock Price History

PDSB Stock News Headlines

PDS Biotechnology Appoints Lars Boesgaard To Succeed Matthew Hill As CFO
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
PDS Biotechnology: Q3 Earnings Insights
A Preview Of PDS Biotechnology's Earnings
PDSB PDS Biotechnology Corporation
The Latest Analyst Ratings for PDS Biotechnology
PDS Biotech to Present at the LD Micro Main Event XVI
See More Headlines
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDSB
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.67
High Stock Price Target
$21.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+237.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.55 per share

Miscellaneous

Free Float
27,997,000
Market Cap
$163.02 million
Optionable
Not Optionable
Beta
2.01
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Frank K. Bedu-Addo Ph.D. (Age 58)
    President, CEO & Director
    Comp: $854.1k
  • Mr. Matthew C. Hill CPAMr. Matthew C. Hill CPA (Age 54)
    CFO, Principal Financial & Accounting Officer
    Comp: $504.09k
  • Ms. Lauren V. Wood M.D. (Age 63)
    Chief Medical Officer
    Comp: $568.5k
  • Dr. Joe J. Dervan
    VP of Research & Development
  • Dr. Gregory L. Conn Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $220.46k
  • Ms. Deanne Randolph
    VP of Commercial Development & Head of Investor Relations
  • Mr. Spencer Brown J.D. (Age 53)
    Senior VP & General Counsel
  • Ms. Nathalie Riebel
    Senior Vice President of Clinical Operations
  • Mr. Sanjay Zaveri
    Senior Vice President of Business Development
  • Ms. Janetta Trochimiuk (Age 60)
    Controller














PDSB Stock Analysis - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings
or view top-rated stocks.

What is PDS Biotechnology's stock price target for 2024?

3 equities research analysts have issued 12-month price targets for PDS Biotechnology's shares. Their PDSB share price targets range from $12.00 to $21.00. On average, they anticipate the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 237.2% from the stock's current price.
View analysts price targets for PDSB
or view top-rated stocks among Wall Street analysts.

How have PDSB shares performed in 2023?

PDS Biotechnology's stock was trading at $13.20 at the beginning of 2023. Since then, PDSB shares have decreased by 60.3% and is now trading at $5.24.
View the best growth stocks for 2023 here
.

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PDSB earnings forecast
.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. During the same quarter last year, the firm posted ($0.23) earnings per share.

What other stocks do shareholders of PDS Biotechnology own?
Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.80%), LPL Financial LLC (0.76%), Commonwealth Equity Services LLC (0.22%), Vontobel Holding Ltd. (0.13%), Simplex Trading LLC (0.00%) and Trexquant Investment LP (0.08%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends
.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PDSB) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -